CN114469880A - Pregabalin composition suitable for powder tabletting and application thereof - Google Patents
Pregabalin composition suitable for powder tabletting and application thereof Download PDFInfo
- Publication number
- CN114469880A CN114469880A CN202210155830.6A CN202210155830A CN114469880A CN 114469880 A CN114469880 A CN 114469880A CN 202210155830 A CN202210155830 A CN 202210155830A CN 114469880 A CN114469880 A CN 114469880A
- Authority
- CN
- China
- Prior art keywords
- pregabalin
- product
- particle size
- raw material
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 title claims abstract description 130
- 229960001233 pregabalin Drugs 0.000 title claims abstract description 127
- 239000000843 powder Substances 0.000 title claims abstract description 33
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 116
- 239000002245 particle Substances 0.000 claims abstract description 92
- 239000013078 crystal Substances 0.000 claims abstract description 67
- 239000000314 lubricant Substances 0.000 claims abstract description 16
- 239000000945 filler Substances 0.000 claims abstract description 14
- 239000000796 flavoring agent Substances 0.000 claims abstract description 8
- 235000013355 food flavoring agent Nutrition 0.000 claims abstract description 8
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims description 73
- 239000002994 raw material Substances 0.000 claims description 66
- 238000002360 preparation method Methods 0.000 claims description 30
- 239000008187 granular material Substances 0.000 claims description 28
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 28
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 18
- 229930195725 Mannitol Natural products 0.000 claims description 18
- 239000000594 mannitol Substances 0.000 claims description 18
- 235000010355 mannitol Nutrition 0.000 claims description 18
- 230000006641 stabilisation Effects 0.000 claims description 17
- 238000011105 stabilization Methods 0.000 claims description 17
- 235000019359 magnesium stearate Nutrition 0.000 claims description 14
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 12
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 12
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 12
- 239000004376 Sucralose Substances 0.000 claims description 11
- 229960000913 crospovidone Drugs 0.000 claims description 11
- 235000019408 sucralose Nutrition 0.000 claims description 11
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 11
- 239000007884 disintegrant Substances 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 238000007873 sieving Methods 0.000 claims description 5
- 238000003825 pressing Methods 0.000 claims description 4
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 3
- 229910002012 Aerosil® Inorganic materials 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 239000000619 acesulfame-K Substances 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229940083542 sodium Drugs 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 108010011485 Aspartame Proteins 0.000 claims description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- 239000004384 Neotame Substances 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 235000010358 acesulfame potassium Nutrition 0.000 claims description 2
- 229960004998 acesulfame potassium Drugs 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 claims description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 2
- 235000019426 modified starch Nutrition 0.000 claims description 2
- 235000019412 neotame Nutrition 0.000 claims description 2
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 claims description 2
- 108010070257 neotame Proteins 0.000 claims description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims 2
- 229910052623 talc Inorganic materials 0.000 claims 2
- DVUFTQLHHHJEMK-IMJSIDKUSA-N Asp-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O DVUFTQLHHHJEMK-IMJSIDKUSA-N 0.000 claims 1
- 239000003205 fragrance Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 60
- 238000004519 manufacturing process Methods 0.000 abstract description 11
- 239000000047 product Substances 0.000 description 99
- 238000000034 method Methods 0.000 description 59
- 239000003826 tablet Substances 0.000 description 45
- 239000000463 material Substances 0.000 description 38
- 230000008569 process Effects 0.000 description 32
- 239000006191 orally-disintegrating tablet Substances 0.000 description 24
- 238000005469 granulation Methods 0.000 description 19
- 230000003179 granulation Effects 0.000 description 19
- 239000000523 sample Substances 0.000 description 17
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 15
- 238000009826 distribution Methods 0.000 description 15
- 239000008108 microcrystalline cellulose Substances 0.000 description 15
- 229940016286 microcrystalline cellulose Drugs 0.000 description 15
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 15
- 235000020985 whole grains Nutrition 0.000 description 14
- 238000009478 high shear granulation Methods 0.000 description 13
- 238000005070 sampling Methods 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 10
- 235000006679 Mentha X verticillata Nutrition 0.000 description 9
- 235000002899 Mentha suaveolens Nutrition 0.000 description 9
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 9
- 235000019640 taste Nutrition 0.000 description 9
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 229940085605 saccharin sodium Drugs 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000012216 screening Methods 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- 239000008186 active pharmaceutical agent Substances 0.000 description 6
- 229940088679 drug related substance Drugs 0.000 description 6
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 5
- 239000012738 dissolution medium Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- 238000005550 wet granulation Methods 0.000 description 5
- 239000002775 capsule Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 4
- 238000010008 shearing Methods 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 3
- 229910000388 diammonium phosphate Inorganic materials 0.000 description 3
- 235000019838 diammonium phosphate Nutrition 0.000 description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 229910052906 cristobalite Inorganic materials 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940009697 lyrica Drugs 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 206010061172 Gastrointestinal injury Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- XINCECQTMHSORG-UHFFFAOYSA-N Isoamyl isovalerate Chemical compound CC(C)CCOC(=O)CC(C)C XINCECQTMHSORG-UHFFFAOYSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010061334 Partial seizures Diseases 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000573 anti-seizure effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 238000007542 hardness measurement Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a pregabalin composition suitable for powder tabletting, wherein the pregabalin as an active component is pregabalin with square crystal habit, the particle size range is D90: 350-600 mu m, and the dosage of the pregabalin composition accounts for 20-50% of the total weight of a prescription. The pregabalin composition also comprises a filler, a disintegrating agent, a flavoring agent, essence and a lubricant. The invention provides another idea, and compared with the common pregabalin bulk drug, the prepared bulk drug has obviously improved compressibility and reduced production cost by preparing the pregabalin bulk drug with a certain particle size range and a specific crystal habit form.
Description
Technical Field
The invention belongs to the field of medicines, and particularly relates to a pregabalin composition suitable for powder tabletting.
Background
The marketed immediate-release oral solid preparation of pregabalin is tablet, capsule and oral disintegrating tablet internationally. Compared with common tablets and capsules, the orally disintegrating tablet can be rapidly disintegrated in the oral cavity under the condition of no water or only a small amount of water, and is particularly suitable for the old, children and patients with dysphagia.
Pregabalin or (S) - (+) -3-aminomethyl-5-methyl-hexanoic acid can bind to the α -2- δ (α 2 δ) subunit of calcium channels and are involved in the endogenous inhibitory neurotransmitter γ -aminobutyric acid (GABA) associated with the regulation of neuronal activity in the brain. As described in U.S. patent No. 5,563,175, pregabalin has anti-seizure activity and is useful for the treatment of the following conditions: epilepsy, pain, physiological disorders associated with psychomotor stimuli, inflammation, gastrointestinal injury, alcoholism, insomnia, fibromyalgia, and various psychiatric disorders including anxiety, depression, mania, and bipolar disorder. Pregabalin has been approved in the united states for the treatment of diabetic peripheral neuropathy, post-herpetic neuralgia, and as an adjunct treatment in adult partial seizures. Pregabalin may be used as an Immediate Release (IR) formulation in a capsule and administered to a patient 2 or 3 times daily (BID or TID). Most patients prefer to take the drug once a day as compared to 2 or more administrations per day, especially for elderly patients and patients taking multiple drugs, and an administration regimen of 1 time a day may generally improve patient compliance. Once daily administration may also reduce or avoid potential side effects by reducing the maximum concentration of the drug in the blood (CMAX) and may also improve drug efficacy by increasing the minimum concentration in the blood (CMIN).
Oral pharmaceutical compositions containing pregabalin present significant formulation challenges. The pregabalin drug molecule is an antagonist of gamma-amino acid (GABA) protein receptors. After being mixed with various auxiliary materials, the filler auxiliary materials such as lactose can accelerate the intramolecular cyclization of the pregabalin to generate lactam impurities. Most of the pregabalin bulk drugs are crystalline crystal particles, and the compressibility is poor, so that the requirements of conventional powder direct compression or dry granulation cannot be met. The direct powder tabletting process is suitable for medicines which are easy to discolor and decompose when exposed to moisture and heat, and has the most remarkable advantages that the equipment and operation cost is reduced, and material particles for direct powder tabletting have good flowability, compressibility and certain fineness or crystal form, otherwise, the phenomena of blanking, unqualified product properties and the like are easy to occur in the production process. Therefore, the difficulty of preparing the pregabalin orally disintegrating tablet preparation is to improve the compressibility of the material.
The pregabalin is a polycrystalline medicine, and comprises an anhydrous type, a semi-water type, crystal forms I-IV and an alpha type. The particular crystalline combination of polymorphic drugs has important effects on the physical properties of the product, such as storage, stability, compressibility, bulk density (which has an important impact on formulation and product manufacture) and dissolution (which has an important impact on determining bioavailability). On the other hand, a characteristic that a crystal spontaneously grows under a certain external condition tends to form a certain morphology is called crystal habit. The habit of crystallization is a short term for its crystal habit and is also called crystal habit, habit of crystallization, habit of crystal and habit of crystal. The classification of crystal habit is usually descriptive, not very strict, and it is difficult to find the definite number of classes and classification criteria. Common crystal habit classifications can be classified into lamellar, dendritic, knife-edge, needle, lenticular, sheet, depending on the crystal appearance; the method is divided into the following components according to the included angles between crystal faces: prisms, pyramids, plates; the method is divided into the following parts according to polyhedrons: cubic, octahedral, dodecahedral; the method is divided into the following according to the aggregation state of single crystals: fibrous, grape-like, radial, block-like; multiple crystal habits may also exist for a single crystal form of the same material. The physical properties of the crystal form and crystal habit of the drug are very important in the processing of the drug, and may affect the compressibility, flowability and the like of the intermediate product.
CN00812588 provides a process for preparing an immediate release pharmaceutical taste-masked granule by granulating a mixed powder of active substance, granule disintegrant, osmotic agent and sweetener using a binder, followed by coating with a coating agent to mask the taste. However, the method has more process steps, the dissolution rate of the coated product is about 10 percent slower than that of a reference preparation (Lyrica) in 5min, the rapid release cannot be realized, the bioavailability is low, and the coated tablet can be swallowed only and cannot be chewed, so the actual taking convenience is not high.
CN103271888 mentions that pregabalin bulk drug has poor compressibility, and provides a prescription which comprises pregabalin drug (10% -50%), disintegrant crospovidone (5% -30%), microcrystalline cellulose (20% -80%), and corrective, glidant and lubricant in balance; the preparation process comprises the following steps: mixing pregabalin, correctant, microcrystalline cellulose and disintegrant in a wet granulating machine, adding appropriate amount of water, granulating, drying, sieving, mixing the sieved granules with the rest adjuvants, and pressing into tablet with desired hardness. The pregabalin powder has poor compressibility, and the pregabalin orally disintegrating tablet developed by the invention overcomes the problem of poor compressibility of pregabalin. According to the invention, multiple tests show that the compressibility of the material can be improved through the granulating process, but the product pressed by the granulated material has obvious taste problem, the taste is gravel and the disintegration is slow; the finished product prepared by the powder direct-pressing process is melted in the mouth and has soft and glutinous mouthfeel. Therefore, to preserve the soft, waxy mouth feel of orally disintegrating tablets of pregabalin, the product mouth feel should not be abandoned in order to use the granulation process to improve the compressibility of the material. Meanwhile, the process steps are complex, the energy consumption of the wet granulation process is high, the time consumption is long, and unnecessary stability risks are caused by the damp and hot conditions in the processing process.
CN111096953 provides a pregabalin orally disintegrating tablet which adopts silicified microcrystalline cellulose and can be directly tableted and a preparation method thereof. It mixes pregabalin and silicified microcrystalline cellulose, then mixes them with other auxiliary materials, then makes them undergo the process of powder direct compression. The prescription comprises pregabalin medicine (10-30%), disintegrant crospovidone (5-20%), filler silicified microcrystalline cellulose, spray-dried mannitol 200SD (10-80%), lubricant (0.5-2%) and corrective (1-3%). The method can improve the compressibility and fluidity of the material, so that the prepared orally disintegrating tablet has excellent stability. However, silicified microcrystalline cellulose is an expensive auxiliary material, the price of the silicified microcrystalline cellulose is 3 to 4 times of that of common microcrystalline cellulose, the dosage proportion of the prescription of the microcrystalline cellulose is 20 to 40 percent, and the increase of the cost is not beneficial to the market sale of products.
Generally, the compressibility of the particles in the process of preparing the pregabalin orally disintegrating tablet can be improved by adding auxiliary materials with better compressibility or reducing the proportion of pregabalin in the prescription, but the problems of tablet weight increase and size increase are caused, and the quantity of tablets produced in a single batch is reduced. The way of adding the binder affects the disintegration behavior of the product and prolongs the disintegration time of the product. The compressibility of the granules can be effectively improved by adopting a wet granulation mode, but the processing cost, the time cost and the like in the preparation process can be increased by adopting the process, and meanwhile, the risk of increasing the impurity content of the product can be increased by contacting with a damp heat factor. At present, most methods for improving the compressibility of granules in the process of preparing the pregabalin orally disintegrating tablet are to add auxiliary materials with better compressibility or carry out wet granulation, and the methods can increase the cost of products and influence the disintegration time limit condition of the products and the like
Disclosure of Invention
The purpose of the invention is as follows: aiming at the defects of the prior art, the invention provides the pregabalin composition suitable for powder tabletting, the compressibility of the material can be obviously improved by selecting the raw material medicines with specific crystal habit and particle size range and further compounding the raw material medicines with a filling agent, a lubricating agent and a disintegrating agent, and the pregabalin orally disintegrating tablet with excellent quality can be prepared by a simple mixed tabletting process.
In order to solve the technical problem, the invention discloses a pregabalin composition suitable for powder tabletting, wherein the pregabalin as an active component is pregabalin with square crystal habit, the particle size range is D90: 350-600 mu m, and the using amount accounts for 20-50% of the total weight of the prescription.
The pregabalin composition also comprises a filler, a disintegrating agent, a flavoring agent, essence and a lubricant.
Specifically, the dosage of the filler is 0.0-80.0%, the flavoring agent is 0.1-15.0%, the disintegrating agent is 1.0-20.0%, the lubricant is 0.5-3.0%, preferably, the dosage of the filler is 30.0-70.0%, the flavoring agent is 1.0-5.0%, the disintegrating agent is 1.0-10.0%, the lubricant is 0.5-3.0%, and the glidant is 0.1-1.0%, wherein the percentages are percentages of the total mass of the prescription.
Wherein the filler is one or two of cellulose derivative and starch derivative. Further, the filler is, for example, cyclodextrin, dextrin, microcrystalline cellulose, pregelatinized starch, sodium carboxymethyl starch, mannitol, sorbitol, xylitol, glucose, methyl cellulose, hydroxypropyl starch, etc.; preferably, the filler is at least one of microcrystalline cellulose, dibasic calcium phosphate dihydrate, mannitol, or lactose.
The disintegrant is at least one of croscarmellose sodium, crospovidone, low-substituted hydroxypropyl cellulose or sodium carboxymethyl starch; the glidant is one or more of superfine silica gel powder, talcum powder and magnesium stearate.
The lubricant is at least one of sodium stearyl fumarate, magnesium stearate, aerosil and talcum powder.
The flavoring agent is one or more of cyclamate, acesulfame potassium (acesulfame K, A-K sugar), aspartame, neotame, sucralose, sucrose, sorbitol, mannitol, and glucose; the essence is natural essence or artificial essence, preferably at least one of natural essence or artificial essence such as milk essence, grape essence, strawberry essence, vanillin, apple essence, orange essence, banana essence, orange oil, etc.
The composition further comprises a glidant, wherein the dosage of the glidant accounts for 0.1-1.0% of the total mass of the prescription, and the glidant is any one or more of superfine silica gel powder, talcum powder and magnesium stearate.
The invention further provides application of the pregabalin composition in preparation of pregabalin tablets.
Furthermore, the invention provides a preparation method of the pregabalin tablet, which comprises the following steps:
(1) carrying out size stabilization on each raw material medicine by using a gate type size stabilization machine, carrying out size stabilization on each raw material medicine by using the gate type size stabilization machine, and after size stabilization, enabling the pregabalin to be the pregabalin with square crystal habit, wherein the particle size range is D90: 350-600 mu m;
(2) mixing the raw materials except the lubricant, sieving, adding the lubricant, and mixing to obtain mixed granules;
(3) and pressing the mixed granules by a tablet machine to obtain a plain tablet with the hardness of 4-6 kg.
Preferably, the mesh opening of the granulating machine is 0.8mm, and the granulating rotating speed is 300-700 rpm. The tablet prepared by the invention can be used for preparing an immediate release preparation for treating epilepsy and neuropathic pain.
Has the advantages that: compared with the prior art, the invention has the following advantages:
(1) through a large number of experiments and researches of the inventor, the invention obtains that: the pregabalin orally disintegrating tablet with excellent quality can be prepared by compounding the pregabalin bulk drug with the particle size range D90 of 350-600 mu m and square crystal habit, a filler, a lubricant and a disintegrant, and can remarkably improve the compressibility of the material. The quick release preparation can realize the quick release of the active ingredient pregabalin, so that the effective blood concentration can be quickly reached after oral administration; compared with the traditional capsule preparation, the quick-release preparation prepared by the invention has the advantages of quick response, quick absorption, stable effect, cool and slightly sweet taste, instant melting in the mouth, soft and glutinous taste, no intolerable bitter taste and capability of improving the compliance of patients.
(2) According to the preparation method, the pregabalin bulk drug is processed by adopting a gate type granulator to obtain the pregabalin bulk drug with specific crystal habit and a certain particle size range, and then the pregabalin bulk drug is mixed with various conventional auxiliary materials to prepare material particles with excellent compressibility by a relatively simple process, so that the material particles are used for preparing the pregabalin orally disintegrating tablets. The process has the advantages of simple operation, mature control standard, low cost, high industrialization degree and the like;
(3) the stability research experiment on the reference preparation shows that the change of quality indexes of the product in the stability investigation process, such as appearance, related substances, dissolution, hardness and the like, can be influenced due to the lower melting point of the lipid auxiliary material, and the use of the auxiliary material with higher price can also increase the product cost. The invention achieves the purposes of reducing the product cost and preparing the stable pregabalin quick-release preparation by simplifying the types of auxiliary materials and controlling the particle size and crystal habit of the pregabalin raw material medicine.
Drawings
The foregoing and/or other advantages of the invention will become further apparent from the following detailed description of the invention when taken in conjunction with the accompanying drawings.
FIG. 1 is a microscope picture of the raw material drug used in product 1;
FIG. 2 is a microscope photograph of the drug substance used in product 2;
FIG. 3 is a graph showing the particle size distribution of the raw material drug used in product 1;
FIG. 4 is a graph showing the particle size distribution of the raw material drug used in product 2;
FIG. 5 is a microscope photograph of the drug substance used in product 3;
FIG. 6 is a microscope photograph of the drug substance used in product 4;
FIG. 7 is a microscope photograph of the drug substance used in product 5;
FIG. 8 is a microscope photograph of the drug substance used in product 6;
fig. 9 is a microscope picture of the drug substance used in product 7.
Figure 10 is a photograph of dissolution profiles of product 1 and product 2 and a reference formulation.
Detailed Description
In order to better understand the present invention, the present invention and its advantages and advantageous effects will be described below by examples of the present invention and experimental data.
In the following examples, the product testing method was as follows:
the method for measuring and sampling the particle size of the raw material medicine comprises the following steps:
in a material bag filled with the whole-grain pregabalin bulk drug, 5g of the sample is respectively sampled from the upper, middle and lower 6 different positions, a sample is synthesized after sampling, 30g of the sample is sampled in total, and the sample is sent for detection of the particle size distribution.
The method for measuring the particle size of the raw material medicine comprises the following steps:
the method for measuring the particle size of the raw material medicine comprises the following steps: weighing 0.3g of dispersant span-85 in a 250ml beaker, adding 120ml of accurately measured n-heptane to obtain span-85 n-heptane solution with a certain proportion, placing the solution in a trace disperser, stirring the solution until the background is stable, measuring a background signal, adding 0.1g of pregabalin sample, stirring the solution for 60s to obtain a sample to be detected with a certain concentration, placing the sample in a trace wet sampling window of a laser particle analyzer, operating a corresponding determination method file according to related parameter items, and taking the arithmetic average of the determination results for 3 times to obtain the particle size data of the raw material drug.
Analyzing the particle size data of the raw material medicines:
the meaning of particle size distribution is that the percentage of particles with different particle sizes in the powder sample in the total volume (or number, etc.) of the particles is measured by a specific instrument and method. D10: the cumulative (percentage of all preceding and following particle sizes added to itself) of a sample corresponds to the particle size at which the particle size distribution reaches 10%. Its physical meaning is that the particles have a size less than (or greater than) 10% of their size. D90: the cumulative particle size distribution of a sample reaches 90% of the corresponding particle size. Its physical meaning is that the particles having a size smaller (or larger) than it account for 90%. D50: the cumulative percent particle size distribution for a sample at 50% corresponds to the particle size. Its physical meaning is that the particle size is greater than 50% of its particles and less than 50% of its particles, D50 also being referred to as the median or median particle size. It does not mean the average particle size of the powder, and means that there are additional parameters to the average particle size of the powder, such as D (4,3), D (3, 2), and so forth. Both D (4,3) and D (3, 2) are volume-based average particle diameters. Wherein D (4,3) are all referred to as "mass moment volume average particle diameter" for short as volume average diameter. The calculation method is that the grain diameter values at two ends of each grain diameter interval are averaged, then the product is multiplied by the corresponding grain size distribution percentage of the interval, and the products are accumulated, namely D (4,3) ═ f 1. D1+ f 2. D2+ f 3. D3+ …. D (3, 2) are all referred to as "volume area average particle diameter", and are simply referred to as "area average particle diameter". The calculation method is to add the percentages of each particle size interval by the average value of the corresponding particle size interval and then to find the reciprocal, i.e., D (3, 2) ÷ (f1 ÷ D1+ f2 ÷ D2+ f3 ÷ D3+ …). Wherein: di represents the average particle size of the ith particle size interval, and fi represents the ith. The relationship between D (3, 2) and D (4,3) can be understood as follows: for laser particle sizers, the more spherical particles are approximated, the more accurate the measurement results. Then, the closer the values of D (3, 2) and D (4,3) are, the more regular the shape of the sample particles is, the more concentrated the particle size distribution is. The larger the difference, the more irregular the shape of the sample particles and the broader the particle size distribution.
The observation method of the crystal habit microscope of the raw material medicine comprises the following steps:
the crystal habit appearance of the raw material medicine is observed and measured by a microscope. Taking 0.01g of the pregabalin bulk drug on a glass slide, and dripping 1 drop of liquid paraffin for dispersion. The parameters of an ocular lens of the microscope are 10 times, the parameters of an objective lens are 5 times, and a picture with uniformly dispersed particles and sufficient illumination is observed and taken.
Fluidity, tablet friability, and maximum tablet hardness measurement methods:
100g of the total mixture was taken and the flowability of the material was measured using an FT-104B angle of repose tester. About 6.5g of the finished product was taken and tablet friability was measured using a CJY-300D type tablet friability tester. The hardness of the finished tablets was measured using a YPD-200C tablet hardness tester.
Example 1
the preparation process flow of the product 1 is as follows:
carrying out door type granulating machine granulation on pregabalin (D90 is 900 mu m, crystal habit is in a shape of long needle and square), sieving with a 0.8mm granulating sieve at a granulating speed of 700rpm, and finishing pregabalin D90 after granulation is 500 mu m, crystal habit is in a shape of square;
secondly, mixing microcrystalline cellulose, the sized pregabalin, mannitol, sucralose, saccharin sodium, polyvinylpolypyrrolidone SH-SL10 and mint essence by using a pyramid mixing barrel according to the dosage in the formula table of the product 1, wherein the mixing speed is 10rpm, and the mixing time is 20 min;
thirdly, screening the mixed granules obtained in the previous step by a 20-mesh vibrating screen, adding magnesium stearate into the screened granules, and mixing by using a square cone mixing barrel, wherein the mixing speed is 10rpm, and the mixing time is 20 min;
and fourthly, directly tabletting the powder by using the mixed particles obtained in the previous step.
mixing pregabalin (D90 is 900 microns, crystal habit is long needle-shaped and square), microcrystalline cellulose, mannitol, sucralose, saccharin sodium, cross-linked povidone SH-SL10 and mint essence by using a pyramid mixing barrel according to the dosage in the formula table of the product 2, wherein the mixing speed is 10rpm, and the mixing time is 20 min;
secondly, screening the mixed granules obtained in the previous step by a 20-mesh vibrating screen, adding magnesium stearate into the screened granules, and mixing by using a square cone mixing barrel, wherein the mixing speed is 10rpm, and the mixing time is 20 min;
and thirdly, directly tabletting the powder by using the mixed particles obtained in the previous step.
Microscope pictures of the raw material medicines used in the product 1 and the product 2 are respectively shown in figure 1 and figure 2, and the particle size distribution of the raw material medicines used in the product 1 and the product 2 is respectively shown in figure 3 and figure 4.
The properties of the raw material medicine and the tablet
Results and conclusions of the experiment
The D90 of the bulk drug of the product 1 after being granulated by the gate granulator is 500 μm, and the difference between D (4,3) and D (3, 2) is 74 μm. The D90 of the bulk drug of the product 2 is 900 μm, and the difference between D (4,3) and D (3, 2) is 575 μm. Compared with the product 2, the product 1 has small difference between the D (3, 2) and D (4,3) of the raw material medicines, which shows that the shape of the raw material medicine particles of the product 1 is more regular and the particle size distribution is centralized, and then the crystal habit is the cubic crystal according to the microscope picture. The difference between D (3, 2) and D (4,3) of the raw material medicine of the product 2 is large, which indicates that the raw material medicine of the product 2 has irregular particle shape and wide particle size distribution, and the crystal habit is uneven mixed crystal of square crystal and long needle crystal according to the microscope picture.
The tablet result shows that the product 1 with the D90 of 500 mu m is mainly in the form of the cristobalite, and has better material flowability than the product 2 with the bulk drug with the crystal habit mainly in the form of the long needle crystal and the cristobalite mixed crystal, and the pressed tablet has lower friability and higher highest compressible hardness. Therefore, the pregabalin bulk drug with the crystal habit mainly being the cubic crystal can effectively improve the flowability and the compressibility of the material and prepare the pregabalin orally disintegrating tablet with excellent properties.
Figure 10 is a dissolution profile for product 1 and product 2 and the reference formulation. The detection is carried out by adopting a 0.06M HCL-paddle method, and the specific detection steps are as follows:
dissolution medium: 0.06M hydrochloric acid solution, and the preparation steps are as follows: measuring 5.4ml of hydrochloric acid, diluting with water to 1000ml, and shaking up to obtain the final product.
Control solution: taking about 16mg of pregabalin control, precisely weighing, placing in a 100mL volumetric flask, adding a dissolution medium to dissolve, quantitatively diluting to a scale, and shaking up (the concentration is about 160 mug/mL). Two portions were prepared in parallel.
Preparing a mobile phase:
(1)0.04M diammonium hydrogen phosphate (pH6.5)
Accurately weighing 5.28g of diammonium hydrogen phosphate and ultrapure water, fixing the volume to 1000ml, adjusting the pH value to 6.5 +/-0.05 by using phosphoric acid, and performing suction filtration.
(2) Mobile phase: 0.04M diammonium hydrogen phosphate (ph 6.5): acetonitrile 90:10
Dissolution conditions:
dissolution medium: 0.06M hydrochloric acid
A dissolution device: paddle method
Rotating speed: 50rpm
Dissolution medium temperature: 37 +/-0.5 DEG C
Sampling volume and fluid infusion volume: 3.5ml of sample is taken, 2ml of waste liquid is dripped and no liquid is replenished.
Volume of dissolution medium: 900 ml.
A sample casting method comprises the following steps: and (4) randomly feeding samples.
Sample solution treatment: the mixture was filtered through a 0.45 μm water filtration head (Jinteng, polyethersulfone, 25mm), and 2ml of the initial filtrate was discarded, and the subsequent filtrate was used as a sample solution.
Sampling time points are as follows: 5. 10, 15 (min).
Detection conditions of a high performance liquid chromatograph:
a chromatographic column: GL Sciences Inertsil ODS-3V.
The oral disintegrating tablet of pregabalin was selected, and the pregabalin was first marketed in Japan in 2017, 02/17, with an english trade name of LYRICA (lereca), a japanese trade name of リリカ OD ingot, and a certificate holder of Pfizer Japan Inc (ファイザー co., ltd.), and the reference preparation was labeled EA 6596. As can be seen from the results, the dissolution curve of the product of the invention is similar to that of the reference preparation, and the in vitro results show that the product of the invention has the same quick effect and quick absorption as the reference preparation to a certain extent.
Example 2
Product 3 prescription table:
product 3 preparation process flow:
carrying out gate type granulating machine granulation on pregabalin (D90 is 900 mu m, crystal habit is in a shape of long needle and square), sieving with a 0.8mm granulating sieve, reducing the granulating speed from 700rpm to 300rpm of the lowest rotation speed of equipment, and obtaining pregabalin D90 with the particle habit of being in a shape of square after granulation, wherein the particle size of the pregabalin is 550 mu m;
secondly, mixing microcrystalline cellulose, the sized pregabalin, mannitol, sucralose, saccharin sodium, crospovidone SH-SL10 and mint essence by using a pyramid mixing barrel according to the dosage in the formula table of the product 3, wherein the mixing speed is 10rpm, and the mixing time is 20 min;
thirdly, screening the mixed granules obtained in the previous step by a 20-mesh vibrating screen, adding magnesium stearate into the screened granules, and mixing by using a square cone mixing barrel, wherein the mixing speed is 10rpm, and the mixing time is 20 min;
and fourthly, directly tabletting the powder by using the mixed particles obtained in the previous step.
The microscope picture of the raw material drug used in the product 3 is shown in fig. 5.
The properties of the raw material medicine and the tablet
Results and conclusions of the experiment
The rotating speed of the gate type granulator is reduced from 700rpm to 300rpm, and compared with the crude drug obtained at the granulating rotating speed of 700rpm, the difference values of D90, D (4,3) and D (3, 2) of the crude drug obtained at the granulating rotating speed of 300rpm have no obvious change. The tablet results show that compared with the product 1 of the raw material medicine obtained at the whole grain rotating speed of 700rpm, the material flowability, the friability of the pressed tablet and the highest pressable hardness of the product 3 of the raw material medicine obtained at the whole grain rotating speed of 300rpm have no obvious difference. Therefore, 700rpm with higher production efficiency is used as the granulating speed parameter of the gate-type granulator in the subsequent process production, and the operation is simple and easy to control.
Example 3
the preparation process flow of the product 4 is as follows:
carrying out size stabilization on the pregabalin (the D90 is 900 mu m, the crystal habit is in a long needle shape and a square shape) by a gate type size stabilization machine, changing a 0.8mm size stabilization screen into a 0.9mm screen, wherein the size stabilization speed is 700rpm, the pregabalin D90 is 700 mu m after size stabilization, and the crystal habit is in a long needle shape and a square shape.
Mixing microcrystalline cellulose, the sized pregabalin, mannitol, sucralose, saccharin sodium, crospovidone SH-SL10 and mint essence by using a pyramid mixing barrel according to the dosage in the formula table of the product 4, wherein the mixing speed is 10rpm, and the mixing time is 20 min;
thirdly, screening the mixed granules obtained in the previous step by a 20-mesh vibrating screen, adding magnesium stearate into the screened granules, and mixing by using a square cone mixing barrel, wherein the mixing speed is 10rpm, and the mixing time is 20 min;
and fourthly, directly tabletting the powder by using the mixed particles obtained in the previous step.
The microscope picture of the raw material drug used in the product 4 is shown in fig. 6.
The properties of the raw material medicine and the tablet
Results and conclusions of the experiment
The door type granulator is replaced by a 0.9mm screen when the screen is 0.8mm, and compared with the bulk drug obtained by 0.8mm screen when the screen is 0.9mm, the differences of D90, D (4,3) and D (3, 2) of the bulk drug obtained by 0.9mm screen when the screen is 0.8mm screen when the screen is 0 mm screen when the screen is whole are obviously increased. The combination of the raw material medicine microscope pictures shows that the pregabalin raw material medicine obtained by granulating through the 0.9mm screen is a long needle-shaped crystal and a square crystal mixed crystal, which is not as round as the raw material medicine obtained by granulating through the 0.8mm screen, and the whole grain size is larger, and D90 is 700 mu m. The tablet results show that, compared with product 1 of the raw material obtained by granulating through a 0.8mm sieve, product 4 of the raw material obtained by granulating through a 0.9mm sieve has slower material flowability, higher friability of the pressed tablet, lower highest compressible hardness and slower disintegration time limit. Therefore, a 0.8mm screen is used as the screen parameter of the gate-type granulator in the subsequent process production, the operation is simple and easy to control, and the product quality can be ensured.
Example 4
Product 5 prescription table:
the preparation process flow of the product 5 is as follows:
carrying out door type granulating machine granulation on pregabalin (D90 is 900 mu m, crystal habit is in a shape of long needle and square), changing a 0.8mm granulating screen into a 0.7mm screen, wherein the granulating speed is 700rpm, the pregabalin D90 is 350 mu m after granulation, and the crystal habit is in a shape of square;
secondly, mixing microcrystalline cellulose, the sized pregabalin, mannitol, sucralose, saccharin sodium, crospovidone SH-SL10 and mint essence by using a pyramid mixing barrel according to the dosage in the formula table of the product 5, wherein the mixing speed is 10rpm, and the mixing time is 20 min;
thirdly, screening the mixed granules obtained in the previous step by a 20-mesh vibrating screen, adding magnesium stearate into the screened granules, and mixing by using a square cone mixing barrel, wherein the mixing speed is 10rpm, and the mixing time is 20 min;
and fourthly, directly tabletting the powder by using the mixed particles obtained in the previous step.
The microscopic picture of the bulk drug used in product 5 is shown in fig. 7.
The properties of the raw material medicine and the tablet
Results and conclusions of the experiment
The door type granulator is replaced by the 0.7mm sieve for the 0.8mm sieve, and compared with the bulk drug obtained by the 0.8mm sieve for granulation, the difference value between D (4,3) and D (3, 2) of the bulk drug obtained by the 0.7mm sieve for granulation is not obviously changed, but D90 is obviously reduced, and the whole particle size is obviously reduced. The combination of the raw material medicine microscope pictures shows that the pregabalin raw material medicine obtained by granulating through a 0.7mm screen is a square crystal which is round, but the whole grain diameter is smaller, and D90 is 350 mu m. The tablet result shows that compared with the product 1 of the raw material medicine obtained by granulating through a 0.8mm screen, the material flowability of the product 5 of the raw material medicine obtained by granulating through a 0.7mm screen is not obviously changed, the friability of the pressed tablet is slightly increased, the highest compressible hardness is slightly reduced, the disintegration time limit is obviously slowed, the raw material medicine is supposed to be more fine powder, and the raw material medicine is easy to adhere to a screen of a disintegration tester during disintegration and cannot pass through smoothly, so that the disintegration time limit is longer. Therefore, a 0.8mm screen is used as the screen parameter of the gate-type granulator in the subsequent process production, the operation is simple and easy to control, and the product quality can be ensured.
Example 5
the preparation process flow of the product 6 is as follows:
crushing pregabalin (D90 is 900 mu m, crystal habit is long needle shape and square shape) by a traditional Chinese medicine crusher for 4s, wherein the obtained crushed pregabalin D90 is 200 mu m, and the crystal habit is square shape;
mixing microcrystalline cellulose, crushed pregabalin, mannitol, sucralose, saccharin sodium, crospovidone SH-SL10 and mint essence by using a pyramid mixing barrel according to the dosage in the formula table of the product 6, wherein the mixing speed is 10rpm, and the mixing time is 20 min;
thirdly, screening the mixed granules obtained in the previous step by a 20-mesh vibrating screen, adding magnesium stearate into the screened granules, and mixing by using a square cone mixing barrel, wherein the mixing speed is 10rpm, and the mixing time is 20 min;
and fourthly, directly tabletting the powder by using the mixed particles obtained in the previous step.
Method for measuring and sampling particle size of raw material medicine
Respectively sampling 5g of the crushed pregabalin bulk drug from 6 different positions of the upper part, the middle part and the lower part of a material bag filled with the crushed pregabalin bulk drug, synthesizing a sample after sampling, sampling 30g in total, and inspecting and detecting the particle size distribution.
The microscopic picture of the bulk drug used in product 6 is shown in fig. 8.
The properties of the raw material medicine and the tablet
Results and conclusions of the experiment
The whole grain procedure of the gate type granulator is changed into the crushing of the traditional Chinese medicine crusher, compared with the whole grain of the raw material medicine obtained by a screen with 0.8mm, the raw material medicine obtained by crushing the raw material medicine for 4s by the traditional Chinese medicine crusher has smaller difference between D (4,3) and D (3, 2), D90 is obviously changed to be smaller, and the whole grain diameter is obviously reduced. The combination of the raw material medicine microscope pictures shows that the pregabalin raw material medicine obtained by crushing with the traditional Chinese medicine crusher is a square crystal which is round, but the whole grain diameter is smaller, and D90 is 200 mu m. Tablet results show that compared with the product 1 of the raw material medicine obtained by granulating through a 0.8mm screen, the material flowability of the product 6 of the raw material medicine obtained by crushing for 4s through the traditional Chinese medicine crusher is slightly reduced, the friability of the pressed tablet is obviously increased, the highest compressible hardness is obviously reduced, and the disintegration time limit is obviously slower, so that the supposedly that the raw material medicine has more fine powder, is easy to adhere to the screen of a disintegration tester during disintegration and cannot pass through smoothly, and the disintegration time limit is longer. Therefore, the traditional Chinese medicine crushing process is difficult to replace a gate-type whole grain process, the crushing effect of the traditional Chinese medicine crushing process is difficult to control, the control standard is difficult to determine, the pregabalin bulk drug with specific crystal habit and certain particle size range cannot be obtained, and the pregabalin orally disintegrating tablets with qualified quality cannot be prepared.
Example 6
Product 7 prescription table:
the preparation process flow of the product 7 is as follows:
crushing pregabalin (D90 is 900 mu m, crystal habit is long needle shape and square shape) by a universal crusher, wherein the crushing screen is 0.8mm, the crushing rotating speed is 1500rpm which is the lowest rotating speed of the equipment, and the crushed pregabalin D90 is 250 mu m, and the crystal habit is square shape;
mixing microcrystalline cellulose, crushed pregabalin, mannitol, sucralose, saccharin sodium, crospovidone SH-SL10 and mint essence by using a pyramid mixing barrel according to the dosage in the formula table of the product 7, wherein the mixing speed is 10rpm, and the mixing time is 20 min;
thirdly, screening the mixed granules obtained in the last step by a 20-mesh vibrating screen, adding magnesium stearate into the screened granules, and mixing by using a square cone mixing barrel, wherein the mixing speed is 10rpm, and the mixing time is 20 min;
fourthly, the mixed particles obtained in the previous step are used for directly tabletting the powder.
Method for measuring and sampling particle size of raw material medicine
Respectively sampling 5g of the universal crushed pregabalin bulk drug from 6 different positions of the upper part, the middle part and the lower part of a material bag, synthesizing a sample after sampling, sampling 30g in total, and inspecting and detecting the particle size distribution.
The microscope picture of the bulk drug used for product 7 is shown in fig. 9.
The properties of the raw material medicine and the tablet
Results and conclusions of the experiment
The whole grain procedure of the gate-type granulator is changed into the crushing of a universal crusher, compared with the raw material medicine obtained by whole grain of the gate-type granulator with a screen of 0.8mm, the raw material medicine obtained by crushing of the universal crusher has smaller difference values of D (4,3) and D (3, 2), the D90 is obviously changed to be smaller, and the whole grain size is obviously reduced. The combination of the raw material medicine microscope pictures shows that the pregabalin raw material medicine obtained by crushing by the universal crusher is a square crystal which is round, but the whole grain diameter is smaller, and D90 is 250 mu m. The tablet results show that compared with the product 1 of the raw material drug obtained by granulating through a 0.8mm screen, the product 7 of the raw material drug obtained by crushing through the universal crusher has slightly reduced material flowability, slightly increased friability of the pressed tablet, slightly reduced highest compressible hardness and obviously slower disintegration time limit. Therefore, the universal crushing process is difficult to replace a portal size stabilization process, the crushing effect of the universal process is difficult to control, the control standard is difficult to determine, the pregabalin bulk drug with specific crystal habit and certain particle size range cannot be obtained, and the pregabalin orally disintegrating tablets with qualified quality cannot be prepared.
Example 7
the preparation process flow of the product 8 is as follows:
dissolving mannitol in water according to a formula table of a product 8, and uniformly stirring to prepare a mannitol solution;
mixing microcrystalline cellulose, pregabalin, sucralose, saccharin sodium, crospovidone SH-SL10 and mint essence in a high-shear granulation pot, wherein the shearing speed is 500rpm, the stirring speed is 200rpm, and the mixing time is 10 min;
thirdly, spraying the mannitol solution into a high-shear granulation pot for granulation at the spraying speed of 15g/s and the atomizing pressure of 0.08MPa, wherein the shearing rotation speed is 1500rpm, the stirring rotation speed is 500rpm, and the granulation time is 3 min;
fourthly, the prepared particles are subjected to 8-8 mm wet granulation and then are put into a fluidized bed, the drying temperature is 45 ℃, and the fluidizing air speed is 60m3Drying for h, and performing gate-type size stabilization on the obtained dried particles by using a 0.8mm screen, wherein the rotation speed of size stabilization is 700 rpm;
adding magnesium stearate into the granules after finishing and mixing by using a square cone mixing barrel, wherein the mixing speed is 10rpm, and the mixing time is 20 min;
and sixthly, tabletting by using the mixed granules obtained in the previous step.
Tablet Properties
Evaluation of tablet mouthfeel
Results and conclusions of the experiment
The whole process of directly tabletting powder is changed into high-shear granulation tabletting, and the tablet result shows that compared with the pregabalin orally disintegrating tablet product 1 obtained by directly tabletting powder, the material flowability of the pregabalin orally disintegrating tablet product 8 obtained by high-shear granulation tabletting is not greatly changed, the friability of the pressed tablet is not greatly changed, the highest compressible hardness is slightly reduced, and the disintegration time limit is obviously slower, and supposedly, the raw material medicine particles are wrapped and covered after high-shear granulation, are not easily dissolved and dispersed during disintegration, so that the material particles are adhered to a screen of a disintegration instrument and cannot pass smoothly, and the disintegration time limit is longer. In the taste evaluation results of the tablets of 4 evaluators, the taste caused by products of different processes is not obviously different, but the taste evaluation of 4 evaluators on the product 8 shows that the product has poor taste and feelings of fine particles and the like, and overall, the taste of the product 1 prepared by directly tabletting powder is better. Therefore, the high-shear granulation tabletting process is not suitable for preparing the pregabalin orally disintegrating tablets, the high-shear granulation tabletting process is complicated, the production efficiency is low, the control standard is difficult to determine, and the pregabalin orally disintegrating tablets with qualified quality are not easy to prepare.
Example 8
Product 9 prescription table:
the preparation process flow of the product 9 is as follows:
dissolving mannitol in water according to a prescription table of a product 9, and uniformly stirring to prepare a mannitol solution;
② the pregabalin (D90 is 900 μm, crystal habit is long needle shape and square shape) is carried out the granulation by a gate type granulator, a 0.8mm granulation screen is adopted, and the granulation speed is 700 rpm.
Mixing microcrystalline cellulose, the sized pregabalin, sucralose, sodium saccharin, crospovidone SH-SL10 and mint essence in a high-shear granulation pot, wherein the shearing speed is 500rpm, the stirring speed is 200rpm, and the mixing time is 10 min;
fourthly, spraying the mannitol solution into a high-shear granulation pot for granulation at the spraying speed of 15g/s and the atomizing pressure of 0.08MPa, wherein the shearing rotation speed is 1500rpm, the stirring rotation speed is 500rpm, and the granulation time is 3 min;
fifthly, carrying out 8-8 mm wet granulation on the prepared particles, and then putting the particles in a fluidized bed, wherein the drying temperature is 45 ℃, and the fluidizing air speed is 60m3Drying for h, and performing gate-type size stabilization on the obtained dried particles by using a 0.8mm screen, wherein the rotation speed of size stabilization is 700 rpm;
sixthly, magnesium stearate is added into the granules after finishing the granules and mixed by using a pyramid mixing barrel, the mixing speed is 10rpm, and the mixing time is 20 min;
seventhly, tabletting by using the mixed particles obtained in the previous step.
Tablet Properties
Results and conclusions of the experiment
The whole process of directly tabletting powder is changed into the process of carrying out gate-type whole granulation on the raw material medicine and then carrying out high-shear granulation tabletting, and the tablet result shows that compared with the pregabalin orally disintegrating tablet product 1 obtained by directly tabletting powder, the material flowability of the pregabalin orally disintegrating tablet product 9 obtained by carrying out gate-type whole granulation on the raw material medicine and then carrying out high-shear granulation tabletting is not changed greatly, the friability of the pressed tablet is not changed greatly, the highest compressible hardness is not changed greatly, but the disintegration time limit is still slow, and after the high-shear granulation, the raw material medicine particles are wrapped and covered by the gate-type whole granulation, and the raw material particles are still not dissolved and dispersed easily during disintegration, so that the material particles are adhered to a sieve of a disintegration instrument, cannot pass smoothly, and the disintegration time limit is longer. Therefore, the direct powder tabletting process is more suitable for preparing the pregabalin orally disintegrating tablets, the high-shear granulation tabletting process is complicated, the production efficiency is low, the control standard is difficult to determine, and the pregabalin orally disintegrating tablets with qualified quality are not easy to prepare.
Summary of the invention
At present, the particle size range of the common pregabalin bulk drug sold on the market is about 800-1100 microns, and the crystal habit is long acicular and square crystal mixed crystal. The pregabalin bulk drug has poor compressibility and flowability, and cannot be used for preparing pregabalin orally disintegrating tablets. The method has the advantages that the door type granulator is used for granulating, the granulating screen is 0.8mm, the granulating rotating speed is 700rpm, the pregabalin bulk drug with the particle size range of 350-600 mu m, the difference range of D (4,3) and D (3, 2) is smaller and 50-150 mu m and the crystal habit is square can be efficiently and easily prepared, the flowability and the compressibility of the pregabalin bulk drug which is commonly sold on the market at present can be effectively improved, and the purposes of simple production process operation, mature control standard, low cost, high industrialization degree and good quality of pregabalin orally disintegrating tablets are achieved. In conclusion, the invention provides another idea, compared with the common pregabalin bulk drug, the prepared total mixed material has obviously improved compressibility by preparing the pregabalin bulk drug with a certain particle size range and a specific crystal habit form, and no extra expensive auxiliary material is used in the process of preparing the total mixed material.
While the methods of the present invention have been described in terms of preferred embodiments, it will be apparent to those of ordinary skill in the art that variations and modifications of the methods and applications described herein, as well as other suitable variations and combinations, may be made to implement and use the techniques of the present invention within the context, spirit and scope of the invention. Those skilled in the art can modify the process parameters appropriately to achieve the desired results with reference to the disclosure herein. It is expressly intended that all such similar substitutes and modifications which would be obvious to those skilled in the art are deemed to be included within the invention.
Claims (10)
1. The pregabalin composition suitable for powder tabletting is characterized in that the pregabalin as an active component is pregabalin with square crystal habit, the particle size range is D90: 350-600 mu m, and the using amount accounts for 20-50% of the total weight of the prescription.
2. The pregabalin composition of claim 1, further comprising a filler, a disintegrant, a flavoring agent, a fragrance, and a lubricant.
3. The pregabalin composition according to claim 2, characterized in that the amount of the filler is 0.0-80.0%, the amount of the flavoring agent is 0.1-15.0%, the amount of the disintegrating agent is 1.0-20.0%, and the amount of the lubricant is 0.5-3.0%, wherein the percentages are percentages of the total mass of the prescription.
4. The pregabalin composition of claim 2, wherein the filler is any one or both of a cellulose derivative and a starch derivative.
5. The pregabalin composition of claim 2, wherein the disintegrant is at least one of croscarmellose sodium, crospovidone, low substituted hydroxypropyl cellulose, or sodium carboxymethyl starch.
6. The pregabalin composition of claim 2, wherein the lubricant is at least one of sodium stearyl fumarate, magnesium stearate, aerosil, and talc.
7. The pregabalin composition according to claim 2, wherein the flavoring agent is any one or more of cyclohexylsulfamate, acesulfame potassium, aspartame, aspartyl alanine amide, neotame, sucralose, sucrose, sorbitol, mannitol, and glucose; the essence is natural essence or artificially synthesized essence.
8. The pregabalin composition according to claim 2, further comprising a glidant, wherein the glidant is any one or more of aerosil, talc and magnesium stearate.
9. Use of a pregabalin composition according to any of the claims 1 to 8 for the preparation of pregabalin tablets.
10. A preparation method of a pregabalin tablet is characterized by comprising the following steps:
(1) carrying out size stabilization on each raw material medicine by using a gate type granulator, and after size stabilization, enabling the pregabalin to be the pregabalin with square crystal habit, wherein the particle size range is D90: 350-600 mu m;
(2) mixing the raw materials except the lubricant, sieving, adding the lubricant, and mixing to obtain mixed granules;
(3) and pressing the mixed granules by a tablet machine to obtain a plain tablet with the hardness of 4-6 kg.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210155830.6A CN114469880B (en) | 2022-02-21 | 2022-02-21 | Pregabalin composition suitable for powder tabletting and application thereof |
| PCT/CN2023/074166 WO2023155682A1 (en) | 2022-02-21 | 2023-02-01 | Pregabalin composition suitable for powder tableting and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210155830.6A CN114469880B (en) | 2022-02-21 | 2022-02-21 | Pregabalin composition suitable for powder tabletting and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114469880A true CN114469880A (en) | 2022-05-13 |
| CN114469880B CN114469880B (en) | 2024-02-02 |
Family
ID=81483251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210155830.6A Active CN114469880B (en) | 2022-02-21 | 2022-02-21 | Pregabalin composition suitable for powder tabletting and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN114469880B (en) |
| WO (1) | WO2023155682A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023155682A1 (en) * | 2022-02-21 | 2023-08-24 | 广州帝奇医药技术有限公司 | Pregabalin composition suitable for powder tableting and use thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060270871A1 (en) * | 2005-05-30 | 2006-11-30 | Khanduri Chandra H | Polymorphic form i of pregabalin and processes for its preparation |
| CN103271888A (en) * | 2013-06-18 | 2013-09-04 | 上海奥科达生物医药科技有限公司 | Pregabalin orally disintegrating tablet and dispersible tablet and preparation method thereof |
| WO2017064192A1 (en) * | 2015-10-14 | 2017-04-20 | Laboratorios Lesvi, S.L. | Pregabalin compositions |
| WO2019238068A1 (en) * | 2018-06-13 | 2019-12-19 | 北京泰德制药股份有限公司 | Sustained-release pregabalin composition and preparation method therefor |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112121020A (en) * | 2019-06-24 | 2020-12-25 | 北京万全德众医药生物技术有限公司 | Preparation method of pregabalin orally disintegrating tablet |
| CN114469880B (en) * | 2022-02-21 | 2024-02-02 | 广州帝奇医药技术有限公司 | Pregabalin composition suitable for powder tabletting and application thereof |
-
2022
- 2022-02-21 CN CN202210155830.6A patent/CN114469880B/en active Active
-
2023
- 2023-02-01 WO PCT/CN2023/074166 patent/WO2023155682A1/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060270871A1 (en) * | 2005-05-30 | 2006-11-30 | Khanduri Chandra H | Polymorphic form i of pregabalin and processes for its preparation |
| CN103271888A (en) * | 2013-06-18 | 2013-09-04 | 上海奥科达生物医药科技有限公司 | Pregabalin orally disintegrating tablet and dispersible tablet and preparation method thereof |
| WO2017064192A1 (en) * | 2015-10-14 | 2017-04-20 | Laboratorios Lesvi, S.L. | Pregabalin compositions |
| WO2019238068A1 (en) * | 2018-06-13 | 2019-12-19 | 北京泰德制药股份有限公司 | Sustained-release pregabalin composition and preparation method therefor |
Non-Patent Citations (2)
| Title |
|---|
| 史雯星等: "普瑞巴林胃滞留缓释片的制备及体外释药机理研究", 《海峡药学》 * |
| 史雯星等: "普瑞巴林胃滞留缓释片的制备及体外释药机理研究", 《海峡药学》, no. 10, 15 October 2018 (2018-10-15) * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023155682A1 (en) * | 2022-02-21 | 2023-08-24 | 广州帝奇医药技术有限公司 | Pregabalin composition suitable for powder tableting and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114469880B (en) | 2024-02-02 |
| WO2023155682A1 (en) | 2023-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2899417T3 (en) | Formulation and direct compression process | |
| ZA200509152B (en) | Bicalutamide forms, compositions, and processes thereof | |
| KR101593360B1 (en) | Bromocriptine formulations | |
| US20120214820A1 (en) | Orally disintegrating pharmaceutical dosage form containing aripiprazole | |
| WO2011010324A1 (en) | Oral pharmaceutical composition of rasagiline and process for preparing thereof | |
| WO2023155682A1 (en) | Pregabalin composition suitable for powder tableting and use thereof | |
| CA3157788A1 (en) | Oral pharmaceutical composition comprising carbamate compound and preparation method therefor | |
| WO2010105822A2 (en) | Dry processing of retigabine | |
| WO2010117035A1 (en) | Complex and process for production thereof, and granules and tablets | |
| Sinha et al. | Extrusion-spheronization: process variables and characterization | |
| NO327452B1 (en) | Powdered mannitol and its preparation | |
| EP3756670A1 (en) | Granular composition, method for producing granular composition, and method for improving elution property of granular composition | |
| CN114129525B (en) | Meclozine orally disintegrating tablet and preparation method thereof | |
| Etman et al. | Floating ranitidine micro particulates: development and in vitro evaluation | |
| US20050266073A1 (en) | Fast disintegrating granules containing bromhexin/bromhexinhydrochloride, process for their preparation, and their use in veterinary medicine | |
| Kumar et al. | Development of oro-dispersible tablet of meclizine by using different superdisintegrating agents | |
| Patel | Formulation and evaluation of gastroretentive floating pellets of nizatidine | |
| EP3377044A1 (en) | Ibuprofen compositions for direct oral administration | |
| CN114028348B (en) | Sildenafil citrate orally disintegrating tablet and preparation method thereof | |
| JP7480983B2 (en) | Levetiracetam-containing preparations | |
| WO2021054453A1 (en) | Amino-acid-containing granules | |
| WO2023151868A1 (en) | Directly compressible mannitol granules | |
| CN108567748A (en) | (S) -2 oxo-1-pyrrolidine ethanamide pharmaceutical composition of -4- hydroxyls and preparation method thereof | |
| CN108567749A (en) | A kind of levo-oxiracetam oral preparation of suitable children taking and preparation method thereof | |
| KR20240025595A (en) | Solid melatonin preparations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Liang Wenwei Inventor after: Liu Feng Inventor after: Tan Xiaofeng Inventor after: Li Junyu Inventor before: Li Junyu Inventor before: Liang Wenwei Inventor before: Liu Feng Inventor before: Tan Xiaofeng |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |